Syncona Regulatory News (SYNC)

Syncona Limited (the "Company")

Director Declaration

22 June 2022

In accordance with the requirements of the Listing Rule 9.6.14R, the Company advises the following change to directorships in other publicly quoted companies, held by the following member of the Board:

Virginia Holmes was appointed to Murray International Trust PLC on 22 June 2022.

Enquiries

Syncona Ltd

Andrew Cossar

Tel: +44 (0) 20 3981 7940

Citco Fund Services (Guernsey) Limited

Company Secretary

Tel: +44 (0) 1481 758200

About Syncona:

Syncona is a leading FTSE250 healthcare company whose purpose is to invest to extend and enhance human life by founding and building a portfolio of global leaders in life science to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

Copies of this press release, a company results presentation, and other corporate information can be found on the company website at: www.synconaltd.com